Search results
Results from the WOW.Com Content Network
This is a major finding because the test is able to “offer[s] a diagnostic biomarker and targeted therapeutic opportunities for Alzheimer’s disease" at a much earlier stage, the researchers ...
Alzheimer's disease (AD) is a neurodegenerative disease that usually starts slowly and progressively worsens. [2] It is the cause of 60–70% of cases of dementia. [2] [15] The most common early symptom is difficulty in remembering recent events. [1]
The United Association of Journeymen and Apprentices of the Plumbing and Pipe Fitting Industry of the United States and Canada, commonly known as the United Association (UA), is a labor union which represents workers in the plumbing and pipefitting industries in the United States and Canada.
Recent research has shown that large soluble APP (sAPP) [9] that are present in CSF may serve as a novel potential biomarker of Alzheimer's disease. In an article published in Nature, a group led by Lewczuk performed a test to observe the performance of a soluble form of APP α and β. A significant increase in sAPP α and sAPP β was found in ...
New research finds a blood test accurately diagnoses Alzheimer’s disease in patients. The blood test was 90% accurate in the study. This blood test is currently available in the U.S.
The free online conference runs from 10 a.m. to 12:30 p.m. Wednesday, and is sponsored by the Alzheimer's Foundation of America. Alzheimer's is one of the top causes of death in the United States ...
Similar to the NINCDS-ADRDA Alzheimer's Criteria are the DSM-IV-TR criteria published by the American Psychiatric Association. [3] At the same time the advances in functional neuroimaging techniques such as PET or SPECT that have already proven their utility to differentiate Alzheimer's disease from other possible causes, [4] have led to proposals of revision of the NINCDS-ADRDA criteria that ...
The Alzheimer's Impact Movement (AIM) is a separately incorporated 501(c)(4) advocacy affiliate of the Alzheimer's Association. AIM works to secure policies to overcome Alzheimer's and dementia, including increased investment in research, improved care and support, and development of approaches to reduce the risk of developing dementia.